QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=21CC80C537D5EC279C3D3E4646FC0D2E;jsessionid=78DC06A9E7ABAF2112F05D7BDE83A2BA;jsessionid=EF392B02AB96969468936A165A8E574C;jsessionid=AB7C7104B7415CBB44C3F11A7BD81C03;jsessionid=C39FDBC797EA4DAFA3BC99802A5CAB98 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=21CC80C537D5EC279C3D3E4646FC0D2E;jsessionid=78DC06A9E7ABAF2112F05D7BDE83A2BA;jsessionid=EF392B02AB96969468936A165A8E574C;jsessionid=AB7C7104B7415CBB44C3F11A7BD81C03;jsessionid=C39FDBC797EA4DAFA3BC99802A5CAB98